Pembrolizumab and Platinum-Based Chemotherapy as First-Line Therapy for Advanced Non –Small-Cell Lung Cancer: Phase 1 Cohorts From the KEYNOTE-021 Study

Standard-of-care first-line therapy for advanced non ―small-cell lung cancer (NSCLC) without sensitizing EGFR mutations or ALK translocation has historically been platinum-doublet chemotherapy with or without maintenance therapy [1]. Adding bevacizumab may improve outcomes in eligible patients with non-squamous histology albeit with added toxicity [ 1–4]; otherwise there has been limited evidence that addition of a third agent provides clinical benefit.

Source: Lung Cancer - August 25, 2018 Category: Cancer & Oncology Authors: Shirish M. Gadgeel, James P. Stevenson, Corey J. Langer, Leena Gandhi, Hossein Borghaei, Amita Patnaik, Liza C. Villaruz, Matthew Gubens, Ralph Hauke, James Chih-Hsin Yang, Lecia V. Sequist, Robert Bachman, Sanatan Saraf, Harry Raftopoulos, Vassiliki Papa Source Type: research